drugset
drugset / Trial / NCT05173025

Effect of Fimasartan on Extended RAS and Vascular Functions in Patients With Type 2 Diabetes and Hypertension

NCT05173025 ↗

Phase 4 Unknown 42 enrolled Seoul National University Bundang Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

In this study, we will assess the change of extended renin-angiotensin system including serum ACE-2 and angiotensin(1-7) levels and subclinical atherosclerosis after using fimasartan (an ARB), compared to amlodipine in hypertensive patients with T2DM.

Timeline

Start
2018-01-01
Primary completion
2022-12-31
Completion
2023-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Fimasartan Small molecule 60 mg Oral

Indications

atherosclerosis secondary hypertension type 2 diabetes mellitus